Strategic partnerships AMILI has active and recent partnerships with East Ventures and Cordlife, indicating openness to collaborations that expand reach in healthcare, microbiome banking, and Asia-wide adoption. Leverage co-marketing, pilot programs, and referral agreements with clinics and hospitals to access new patient cohorts.

Expansion-ready funding With Series A funding and a revenue range in the multi-million dollars, AMILI is positioned for regional scaling in Southeast Asia and Greater Asia. Target enterprise customers, healthcare networks, and government-backed health initiatives seeking precision gut health solutions.

Clinical and consumer bridge AMILI blends clinical services (microbiome testing, restoration therapy) with consumer-focused products (AMILI Optimise, targeted probiotics). There is an opportunity to upsell to clinics and wellness centers that require end-to-end gut health programs for chronic conditions.

Data and databases Maintains Southeast Asia's largest multi-ethnic Asian gut microbiome database and a gut microbiome transplant bank. This data asset can be offered as a service or used to develop monetizable screening tools, predictive insights, and partner-driven research programs.

Tech-enabled scale A tech stack spanning iCIMS, Contentful, Google Workspace, and collaboration tools suggests readiness for enterprise sales motions. Position AMILI as a scalable, compliant platform for hospital systems, clinics, and research institutions seeking integrated microbiome solutions.